CClinicalTrials.gg
CompletedNCT03428633Updated Oct 13, 2023

Thoracic Paravertebral Blocks in Open Nephrectomy

A Phase 2 interventional study of Ropivacaine and Morphine in Nephrectomy and Analgesia, sponsored by Asklepieion Voulas General Hospital. Completed at 1 site in Greece. Open to participants aged 14 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Asklepieion Voulas General Hospital · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
14 Years to 80 Years
Sex
All
01

Study summary

60 patients ASA I-III, undergoing open nephrectomy will be randomly assigned into one of two groups, namely group A (n=30), where a thoracic paravertebral block will be performed preoperatively and a paravertebral catheter for continuous and patient controlled bolus local anesthetic (ropivacaine) doses will be inserted and group B (n=30) where morphine IV will be administered at the beginning and the end of operation and postoperatively through patient controlled IV doses. NRS scores in static and dynamic conditions, complications, patient satisfaction, oxidative stress (through lactic acid, superoxide dismutase, malondialdehyde) and NGAL pre- and postoperatively, will be recorded.

02

Conditions studied

  • Nephrectomy
  • Analgesia
03

Who can participate

Ages eligible
14 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Physical status according to American Society of Anesthesiologists (ASA) I-III
  • Patients scheduled for open nephrectomy

Exclusion criteria

Exclusion Criteria:

  • Previous operation on same kidney
  • Contraindication of paravertebral block or any of the agents used in the protocol
  • BMI above 32
  • Any concurrent malignancy not cured
  • Serious psychiatric, mental and cognitive disorders
  • Block failure
  • Chronic pain
  • Severe kidney disfunction
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group A

    Thoracic paravertebral block using ropivacaine

    Drug: Ropivacaine

  • Active comparator
    Group B

    Morphine IV

    Drug: Morphine

Interventions

  • DrugRopivacaine

    Paravertebral block using ropivacaine preoperatively and postoperatively

  • DrugMorphine

    Morphine intraoperatively and postoperatively

05

What researchers measure

Primary outcomes

  1. Postoperative pain

    Numerical Rating Scale (NRS) scores (Range 0-10, 0=no pain, 10=the worse pain ever)

    Time frame: 48 hours

  2. Oxidative stress - lactic acid (mmol/L)

    Time frame: 24 hours

  3. Oxidative stress - superoxide dismutase (units/ml)

    Time frame: 24 hours

  4. Oxidative stress - malondialdehyde (nmol/mg protein)

    Time frame: 24 hours

  5. Oxidative stress - neutrophil gelatinase-associated lipocalin (NGAL) (ng/ml)

    Time frame: 24 hours

Secondary outcomes

  1. Complications

    Time frame: 48 hours

  2. Patient satisfaction

    Patients asked whether they would choose the same anaesthetic management in a future operation: Yes/No

    Time frame: 48 hours

  3. Patient mobilization

    Patient reporting time of first standing to the side of the bed

    Time frame: 7 days

  4. Intestinal function

    Time of first passing of rectal gas, reported by the patient

    Time frame: 7 days

  5. Chronic pain

    Using of Graded Chronic Pain Scale (GCPS) Grade 0: No pain in prior 6 months Grade 1: Low Intensity - Low Disability Grade II: High Intensity Characteristic Pain Intensity - Low Disability Grade III: High Disability - Moderately Limiting Grade IV: High Disability - Severely Limiting

    Time frame: 6 months

06

Study locations

1 site
  • Asklepieion Hospital of Voula
    Athens, 16673, Greece
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03428633
Lead sponsor
Asklepieion Voulas General Hospital
Collaborators
Michail Tsagkaris, Chryssoula Staikou, Ioannis Karavokyros
Responsible party
Alexandros Makris (Consultant Anaesthesiologist, Asklepieion Voulas General Hospital) — Principal investigator
First posted
Feb 9, 2018
Start date
Mar 9, 2018
Primary completion
Feb 1, 2021
Completion
Feb 1, 2023
Last update
Oct 13, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion